Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Clements

Gastroenterology Charlotte, NC Medical Doctor

NPI 1881612364 CMS profile 85353

1225 Harding Pl Ste 5100, Charlotte, NC 28204

Open in the dashboard

General payments

$6,441

325 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Clements of Charlotte, NC is reported in the CMS Open Payments database as having received $6,441 across 325 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,000 25
2024 General $1,031 43
2023 General $744 39
2022 General $825 49
2021 General $654 35
2020 General $703 37
2019 General $1,485 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Clements
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to John Clements were reported at $1,000. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year John Clements Gastroenterology median Middle half National median
2019 $1,485 $417 $126–$1,100 $163
2020 $703 $224 $74–$624 $114
2021 $654 $352 $106–$1,054 $132
2022 $825 $448 $129–$1,270 $149
2023 $744 $533 $150–$1,390 $160
2024 $1,031 $605 $160–$1,606 $164
2025 $1,000 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,808 105 payments
  2. Stryker Corporation $758 5 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $499 31 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $434 28 payments
  5. Genzyme Corporation $401 17 payments
  6. Janssen Biotech, Inc. $373 24 payments
  7. Celgene Corporation $294 21 payments
  8. Intercept Pharmaceuticals, Inc. $183 10 payments
  9. Novo Nordisk Inc $181 7 payments
  10. Ferring Pharmaceuticals Inc. $160 9 payments
  11. Other $1,352 68 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,036 322 payments
  2. Travel and Lodging $391 2 payments
  3. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. HUMIRA $614 34 payments
  2. DUPIXENT $401 17 payments
  3. MAVYRET $397 24 payments
  4. RINVOQ $390 22 payments
  5. XIFAXAN $387 25 payments
  6. EASYFUSE $337 2 payments
  7. STELARA $318 22 payments
  8. ZEPOSIA $267 20 payments
  9. SKYRIZI $183 5 payments
  10. Entyvio $181 13 payments
  11. Other $3,454 181 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

3,100

Median for Gastroenterology: 569

Drug cost

$1,015,807

Median for Gastroenterology: $104,976

Branded share of claims

19.1%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entyvio Vedolizumab Brand 24 $207,295
Humira(Cf) Pen Adalimumab Brand 21 $164,226
Xifaxan Rifaximin Brand 42 $136,252
Ocaliva Obeticholic Acid Brand 12 $110,791
Humira Pen Adalimumab Brand 12 $80,977
Linzess Linaclotide Brand 65 $51,307
Zenpep Lipase/Protease/Amylase Brand 16 $43,311
Creon Lipase/Protease/Amylase Brand 19 $36,358
Dexlansoprazole Dr Dexlansoprazole Brand 73 $32,800
Movantik Naloxegol Oxalate Brand 57 $30,851

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$122,406

Medicare's payments for the services billed

Medicare patients

571

Average age 74

Services billed

1,370

305 women, 266 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Ischemic heart disease 30%
Diabetes 28%
Chronic kidney disease 25%
Atrial fibrillation 19%
Heart failure 18%
Depression 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $98
  • Regeneron Healthcare Solutions, Inc. $22
$120 — —
OMVOH
  • Lilly USA, LLC $86
$86 — —
LINZESS
  • AbbVie, Inc. $54
$54 65 —
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $50
$50 16 —
CREON
  • AbbVie, Inc. $41
$41 19 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

325 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record